Viking Therapeutics, Inc. (VKTX) — Financial statements
Income statement, balance sheet, and cash flow for Viking Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.43 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 345↑239.4% | 102↑59.3% | 64↑17.6% | 54↑20.6% | 45 | |
| General & Administrative Expenses | 48↓1.8% | 49↑33.1% | 37↑129.6% | 16↑50.6% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 48↓1.8% | 49↑33.1% | 37↑129.6% | 16↑50.6% | 11 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 393↑160.6% | 151↑49.7% | 101↑43.3% | 70↑26.4% | 56 | |
| Total Costs & Expenses | 393↑160.6% | 151↑49.7% | 101↑43.3% | 70↑26.4% | 56 | |
| Operating Results | ||||||
| Operating Income | -393↓160.6% | -151↓49.7% | -101↓43.3% | -70↓26.4% | -56 | |
| Depreciation & Amortization | 0.43↑24.6% | 0.35↑18.5% | 0.29↑0.3% | 0.29↓1.7% | 0.30 | |
| EBITDA | -393↓161.2% | -151↓49.8% | -101↓43.5% | -70↓26.5% | -55 | |
| EBIT | -393↓160.6% | -151↓49.7% | -101↓43.3% | -70↓26.4% | -56 | |
| Interest & Other Income | ||||||
| Net Interest Income | 34↓17.5% | 41↑173.5% | 15↑875.9% | 2↑123.4% | 0.69 | |
| Interest Income | 34↓17.7% | 41↑172.6% | 15↑845.2% | 2↑126.0% | 0.70 | |
| Interest Expense | 0.06↓40.4% | 0.09↑6.8% | 0.09↑49.2% | 0.06↑227.8% | 0.02 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 34↓17.7% | 41↑174.3% | 15↑903.5% | 1↑115.0% | 0.69 | |
| Income Before Tax | -360↓227.1% | -110↓28.0% | -86↓24.7% | -69↓25.2% | -55 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -360↓227.1% | -110↓28.0% | -86↓24.7% | -69↓25.2% | -55 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -360↓227.1% | -110↓28.0% | -86↓24.7% | -69↓25.2% | -55 | |
| Bottom-Line Net Income | -360↓227.1% | -110↓28.0% | -86↓24.7% | -69↓25.2% | -55 | |
| EPS (Basic) | -3.19↓215.8% | -1.01↓11.0% | -0.91↓3.4% | -0.88↓25.7% | -0.70 | |
| EPS (Diluted) | -3.19↓215.8% | -1.01↓11.0% | -0.91↓3.4% | -0.88↓25.7% | -0.70 | |
| Weighted Average Shares | 113↑3.3% | 109↑15.6% | 94↑22.8% | 77↓0.5% | 77 | |
| Weighted Average Diluted Shares | 113↑3.3% | 109↑15.6% | 94↑22.8% | 77↓0.5% | 77 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.